Idorsia Ltd (OTCMKTS:IDRSF) Shares Shorted: Short Interest Down 35.0% in October

Idorsia Ltd (OTCMKTS:IDRSF) was the recipient of a significant drop in short interest in October. As of October 15th, there was short interest totaling 6,184,041 shares, a drop of 35.0% from the September 30th total of 9,515,618 shares. Based on an average daily trading volume, of 2,261 shares, the days-to-cover ratio is presently 2,735.1 days.

Idorsia Price Performance

Shares of OTCMKTS IDRSF opened at $4.95 on Monday. Idorsia has a 52-week low of $3.50 and a 52-week high of $8.19. The business has a 50-day moving average price of $5.85 and a 200 day moving average price of $5.67.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on IDRSF. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Idorsia in a report on Monday, August 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Idorsia in a research report on Monday, September 14th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

About Idorsia

Idorsia Ltd. is a Swiss biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. Its research activities span areas including cardiovascular disease, central nervous system disorders, immunology and rare diseases. The company operates from its headquarters in Allschwil, Switzerland, and serves international pharmaceutical markets through its own commercial operations and collaboration arrangements.

Idorsia’s commercial portfolio includes QUVIVIQ (daridorexant), an orexin receptor antagonist used to treat insomnia in eligible adults, and PIVLAZ (clazosentan), a therapy intended to reduce the risk of cerebral vasospasm and related complications following aneurysmal subarachnoid hemorrhage.